View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 27, 2017

Sage Therapeutics begins dosing in Phase I trial of SAGE-718

US-based biopharmaceutical firm Sage Therapeutics has begun dosing healthy volunteers in its Phase I clinical trial of SAGE-718.

US-based biopharmaceutical firm Sage Therapeutics has begun dosing healthy volunteers in its Phase I clinical trial of SAGE-718.

SAGE-718 is an oral, oxysterol-based, N-methyl-D-aspartate (NMDA) receptor, positive allosteric modulator (PAM).

The positive modulation of NMDA receptors reportedly has the potential for treating disorders characterised by cognitive, neurological and behavioural symptoms.

The double-blind, placebo-controlled, single ascending dose Phase I trial is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamic effects of the product when administered orally.

Sage chief executive officer Jeff Jonas said: “Advancing SAGE-718 into Phase I clinical development represents a significant achievement in broadening our clinical pipeline beyond GABA, with a new product development platform focused on a novel mechanism to modulate the NMDA receptor system.

"The top-line results from the Phase I trial are expected to be available in the second half of this year."

“Loss of NMDA function may have a significant impact in many neuro psych disorders, and SAGE-718 and our novel follow-on compounds have the potential to further extend our pipeline into a broad array of CNS indications."

According to the data from preclinical studies, SAGE-718 showed improved social behaviour in animal model with NMDA hypofunction, and mitigated deficits associated with behavioural and electrophysiological in a model with irregular cholesterol regulation.

The top-line results from the Phase I trial are expected to be available in the second half of this year.  

Sage develops medicines for central nervous system (CNS) disorders, targeting GABA and NMDA receptor systems.


Image: Sage Therapeutics' new trial for SAGE-718. Photo: courtesy of foto76/FreeDigitalPhotos.net.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena